The US has approved Datroway, a breakthrough cancer treatment from AstraZeneca and Daiichi Sankyo, for patients battling advanced non-small cell lung cancer.
This marks the first time Datroway has been cleared to treat this form of lung cancer, giving fresh hope to adults who have already undergone prior treatments. The approval opens doors to wider access in the world’s largest pharmaceutical market.
Also Read: Pakistan’s First Colorectal Cancer Patient Receives Life-Saving Liver Transplant
Datroway is a type of antibody-drug conjugate, often called a “guided missile” therapy, targeting the TROP2 protein found on tumor cells. Unlike traditional chemotherapy, it aims to attack only cancerous cells, reducing damage to healthy ones. It is already used in treating certain breast cancers.
AstraZeneca announced a $45 million milestone payment to Daiichi after the approval. The two companies have been working together since 2020 under a multibillion-dollar deal to develop and market Datroway.
